Alpine Immune Sciences, Inc.
ALPNDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Povetacicept | Phase 3 | Lupus Nephritis | - | - |
ALPN-101 | Phase 2 | Systemic Lupus Erythematosus | - | - |
Lupus Nephritis
1 drug in this indication
Systemic Lupus Erythematosus
1 drug in this indication
Immunoglobulin A Nephropathy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Alpine Immune Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Alpine Immune Sciences, Inc.'s (ALPN) pipeline across Phase 3, Phase 2. Its lead program is Povetacicept (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alpine Immune Sciences, Inc.'s next FDA catalyst?→
Alpine Immune Sciences, Inc.'s (ALPN) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALPN biotech catalysts?→
Add ALPN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alpine Immune Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.